Tradestie Institutional Equity Comparison Engine · Market Close May 04, 2026

MIGI vs EKSO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EKSO Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–3 Matrix Metrics)

EKSO Overall Winner 6-Pillar Tally: MIGI 1 – 3 EKSO (2 Tie) Matrix Metrics: MIGI 3 – 7 EKSO

As of May 04, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Mawson Infrastructure Group Inc. (MIGI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MIGI carries a Unified Composite Score of 56.4/100 (HOLD) at $4.71 (5.5x Forward P/E, -456.2% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MIGI vs EKSO
MIGI NASDAQ
Mawson Infrastructure Group Inc. Common Stock
Finance Services
$4.71
+12.41% 1D
Market Cap $23.0M
TTM Revenue $40M
Forward P/E 5.5x
Beta / 30D Vol 13.79β · 314% Vol
Unified Composite Score
56.4 / 100 HOLD
Tech 40.0 Fund 51.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.5 · SMA20: $5.02 · SMA50: $3.62
EKSO NASDAQ Head-to-Head Winner
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65

6-Pillar Scorecard Institutional Category Breakdown (MIGI 1 – 3 EKSO)

Columns: Metric · MIGI · EKSO
1. Valuation Multiples MIGI
Forward P/E 5.5x N/M
Trailing P/E 5.5x N/M
PEG Ratio N/M N/M
EV / Revenue 1.3x 3.3x
2. Growth & Scale EKSO
Revenue Growth (YoY) -78.5% -38.3%
Earnings Growth (YoY) -97.7% +0.0%
TTM Revenue (USD) $40M $13M
Market Cap $23.0M $42.0M
3. Profitability & Quality EKSO
Gross Margin 43.6% 53.5%
Operating Margin -456.2% -119.7%
Net Profit Margin -59.5% -91.4%
Return on Equity (ROE) -461.2% -107.6%
4. Balance Sheet & Cash Flow EKSO
Cash Generation (TTM) -$24M -$11M EBITDA
Cash Flow Margin -59.6% -86.0% EBITDA Mgn
Net Cash / Leverage $27M Net Debt (6.78x D/E) $2.54 Book/Sh · -107.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Capital Markets Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MIGI (3) vs EKSO (7)
Institutional Metric MIGI EKSO Criterion Row Edge
Market Capitalization
Scale
$23.0M $42.0M Larger Scale EKSO
Trailing P/E Ratio
Valuation
5.5x N/M Lower Multiple MIGI
Forward P/E Ratio
Valuation
5.5x N/M Lower Multiple MIGI
Revenue Growth (YoY)
Growth
-78.5% -38.3% Higher Growth EKSO
Operating Margin (TTM)
Profitability
-456.2% -119.7% Higher Margin EKSO
Net Profit Margin
Profitability
-59.5% -91.4% Higher Margin MIGI
Return on Equity (ROE)
Capital Efficiency
-461.2% -107.6% Higher ROE EKSO
52-Week Range Position
Momentum
28% ($0–$16) 87% ($0–$14) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
13.79β · 314% Vol 2.16β · 76% Vol Lower Realized Risk EKSO
Unified Institutional Score
Composite Signal
56.4 / 100 (HOLD) 58.1 / 100 (HOLD) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$40M $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
43.6% 53.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.3x EV/Rev N/M PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($27M Net Debt (6.78x D/E)) -$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MIGI +133.83 pp
MIGI: +147.89% · EKSO: +14.06%
3M Horizon EKSO +28.98 pp
MIGI: +5.61% · EKSO: +34.59%
6M Horizon MIGI +116.37 pp
MIGI: +248.89% · EKSO: +132.52%
1Y Horizon EKSO +121.76 pp
MIGI: -64.12% · EKSO: +57.64%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MIGI vs EKSO. Trailing 12-month operating profitability (MIGI -456.2% vs EKSO -119.7%) and valuation multiples (MIGI 5.5x vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MIGI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40M
Gross Margin43.6%
Op. Margin-456.2%
ROE / Fwd P/E-461.2% · 5.5x
EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MIGI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MIGI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MIGI Moat Profile Cyclical / Execution-Driven Positioning
Capital Markets Operator
Competes within the Capital Markets value chain with $23.0M market capitalization and -456.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MIGI vs EKSO Key Questions & Quantitative Answers

As of May 04, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Mawson Infrastructure Group Inc. (MIGI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MIGI carries a Unified Composite Score of 56.4/100 (HOLD) at $4.71 (5.5x Forward P/E, -456.2% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin). Technically, MIGI sits in a Neutral phase (RSI 49.5, UNCLASSIFIED options structure) and EKSO sits in a Markup phase (RSI 60.4, UNCLASSIFIED options structure).

EKSO leads the Growth & Scale pillar: MIGI posts -78.5% YoY revenue growth and -97.7% YoY earnings growth on $40M TTM revenue (43.6% gross margin, -456.2% operating margin), compared with EKSO at -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin). On trailing 12-month operating scale, MIGI generates $40M in USD-normalized revenue versus $13M for EKSO. In operating R&D and SG&A reinvestment, MIGI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EKSO.

MIGI screens cheaper on headline valuation multiples. MIGI trades at 5.5x Forward P/E, 5.5x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-59.6% FCF margin), whereas EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MIGI (-461.2% ROE) versus EKSO (-107.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MIGI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (13.79β · 314% Vol realized risk). By comparison, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 04, 2026. For educational research only; not investment advice.